In a pre-clinical setting, galectin-3 inhibition results in a reduction in myocardial fibrosis and improvement of LV function [30]; however, to date, its favorable effects are difficult to demonstrate in patients [29]. Here, LGALS3 is linked to Myocardial fibrosis.